RE:HSC TESTING POST CRYOPRESERVATION

From: D. Robert Sutherland (rob.sutherland@utoronto.ca)
Date: Tue Aug 15 2000 - 10:13:31 EST


Re: HSC TESTING AFTER CRYOPRESERVATION
In response to Lisa and  the other respondents, it is correct that very
few laboratories are performing CD34+ cell enumeration on post-thawed
samples.  It is also true that FACHT have little if anything to say
about measuring engraftment potential by flow.
While there are a variety of reasons for this, the most significant one
is that most flow methodologies in the past were incapable of accurately
measuring viable CD34+ cells in such samples.  This was due to the fact
that the absolute CD34+ cell count was determined by ‘two platform’
methodologies (“%CD34+ events” from flow multiplied by the absolute
leucocyte count from a hematology analyser).  Both values are virtually
impossible to determine with accuracy on post-thawed samples (and even
some  “fresh” ones).  With the advent of the single platform version
(Cytometry (Communications in Clinical Cytometry) 34:61-70 1998.) of the
ISHAGE protocol (J. Hematotherapy 5:213-226,1996), that utilises
fluorescent counting beads and the viability dye 7-AAD, it is now
possible to reliably measure the absolute viable CD34+ cell count in
virtually any source of hematopoietic cells, including post-thawed
samples.  It is essential that after thawing, samples are handled and
tested in such a way that cell viability is not compromised during
laboratory processing. Aliquots of packs which have been handled
differently than the actual product will give little information on the
product actually reinfused into the patient.  At one of our institutions
(MK/ICY) the thawed product is washed and resuspended in a unit of
packed cells before reinfusion. This product is monitored for viable
CD34+  cells to ensure there has not been unacceptable loss due to
processing.
In the clinical setting of peripheral blood stem cell transplantation,
most studies that have correlated the CD34+ cell dose infused with
engraftment have been performed on pre-cryopreserved specimens. Such
studies have  noted a number of ‘outliers’ in the data sets and a reason
for this may be related to post thaw viability.
In general, if samples are collected, processed and cryopreserved in a
timely manner, using cGMP, it is doubtful whether post-thaw flow
analysis will provide significant useful information to the
tranplanter.  However, if samples are mishandled or shipped prior to
storage, or the cell concentration is too high in the pack and was not
diluted immediately prior to processing, or there was a high
number/concentration of neutrophils in the pack, for either ‘technical’
reasons, or due to the use of different cytokine mobilisation cocktails,
recovery of viable CD34+ cells can be severely compromised.  We have
seen several examples of this, and it is  important when there are
concerns over product handling to have available a single platform flow
method for the enumeration of viable CD34+ cells.  In such cases, if a
‘pilot’ QC vial of frozen cells is available (or the actual product as
mentioned above) it can be analysed and intelligent decisions can be
taken regarding the safety of using the frozen product, as opposed to
re-mobilising/collecting the patient.
We have also performed many analyses on pre- and post-thawed cord blood
samples for the local cord blood bank, to optimize the collection,
processing, storage and recovery of viable CD34+ cells.  To our
knowledge, the single platform based ISHAGE protocol, that also
underlies the ‘Basic Protocol’ for the enumeration of CD34+ cells for
‘Current Protocols in Cytometry (Unit 6.4), is the only flow-based
method able to perform this type of analysis.
At the current time, we are developing a linked web-site dedicated to
the enumeration of CD34+ cells by flow cytometry with the International
Society for Hematotherapy and Graft Engineering (www.ishage.org).  When
completed (soon) this site will contain downloadable templates and
listmode files (from both Macintosh-based BDB FACS and PC-based Coulter
XL instruments) of the single platform methodology used for the
measurement of viable CD34+ cells.  Meanwhile, we can e-mail copies of
these files to any interested individuals.  (For BDB platform contact
rob.sutherland@utoronoto.ca and for Coulter XL files contact
mike.keeney@lhsc.on.ca).

Rob Sutherland, Mike Keeney, Rakash Nayar, Ian Chin-Yee



This archive was generated by hypermail 2b29 : Sat Mar 10 2001 - 19:31:29 EST